Literature DB >> 22707299

Analysis of driver mutations in female non-smoker Asian patients with pulmonary adenocarcinoma.

Shengxiang Ren1, Peng Kuang, Limou Zheng, Chunxia Su, Jiayu Li, Bing Li, Xiaoxia Chen, Yongshen Wang, V KimCurran, Lu Liu, Qiong Hu, Jie Zhang, Liang Tang, Caicun Zhou.   

Abstract

Previous studies have revealed that EGFR mutation and/or EML4-ALK gene fusion rate was higher in the non-smoker Asian females with pulmonary adenocarcinoma. The aim of this study is to determine the distribution of known oncogenic driver mutations in the female non-smoker Asian patients with pulmonary adenocarcinoma. 104 consecutively resected lung adenocarcinomas from 396 non-smoker females (less than 100 cigarettes in a lifetime) at a single institution (Tongji University, Shanghai, China) were analyzed for mutations in EGFR, EML4-ALK, KRAS, HER2, BRAF, and PIK3CA. 73 (70.2 %) tumors harbored EGFR mutations; among these, 28 were deletions in exon 19, 44 were L858R missense changes, and eight were T790M mutations. 10 (9.6 %) harbored EML4-ALK fusions, two harbored KRAS mutations, two harbored BRAF mutations, and two harbored PI3K mutations. A majority of the mutations were mutually exclusive, except two with EGFR mutation and BRAF mutation, one with EML4-ALK fusions and PI3K mutation. Thus, 82.7 % (86 of 104; 95 % CI, 75.4-90.0 %) of lung adenocarcinomas from non-smoker females were found to harbor the well-known oncogenic mutations in five genes. Lung cancer in non-smoking Asian females is a distinct entity, with majority of this subgroup being developed by the oncogenic mutations. The prospective mutation examination in this population will be helpful for devising a targeted therapy for a majority of the patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22707299     DOI: 10.1007/s12013-012-9384-8

Source DB:  PubMed          Journal:  Cell Biochem Biophys        ISSN: 1085-9195            Impact factor:   2.194


  26 in total

1.  Cancer genes in lung cancer: racial disparities: are there any?

Authors:  Ahmed El-Telbany; Patrick C Ma
Journal:  Genes Cancer       Date:  2012-07

Review 2.  Lung cancer mutations and use of targeted agents in Hispanics.

Authors:  W Douglas Cress; Alberto Chiappori; Pedro Santiago; Teresita Muñoz-Antonia
Journal:  Rev Recent Clin Trials       Date:  2014

3.  Racial and Ethnic Differences in the Epidemiology and Genomics of Lung Cancer.

Authors:  Matthew B Schabath; Douglas Cress; Teresita Munoz-Antonia
Journal:  Cancer Control       Date:  2016-10       Impact factor: 3.302

Review 4.  Current status of research and treatment for non-small cell lung cancer in never-smoking females.

Authors:  Shin Saito; Fernando Espinoza-Mercado; Hui Liu; Naohiro Sata; Xiaojiang Cui; Harmik J Soukiasian
Journal:  Cancer Biol Ther       Date:  2017-05-11       Impact factor: 4.742

5.  Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.

Authors:  Liza C Villaruz; Mark A Socinski; Shira Abberbock; Lynne D Berry; Bruce E Johnson; David J Kwiatkowski; A John Iafrate; Marileila Varella-Garcia; Wilbur A Franklin; D Ross Camidge; Lecia V Sequist; Eric B Haura; Mark Ladanyi; Brenda F Kurland; Kelly Kugler; John D Minna; Paul A Bunn; Mark G Kris
Journal:  Cancer       Date:  2014-10-01       Impact factor: 6.860

Review 6.  Lung cancer molecular epidemiology in China: recent trends.

Authors:  Caicun Zhou
Journal:  Transl Lung Cancer Res       Date:  2014-10

7.  Preparation and identification of an anti-idiotypic antibody antagonist (FG8) for EGFR that shows potential activity against liver cancer cells.

Authors:  Yurong Wang; Fangping He; Helin Zhang; Ying Cao; Yaqing Zhang; Yun Ling; Aliya Rehati
Journal:  Biotechnol Lett       Date:  2020-11-03       Impact factor: 2.461

Review 8.  Lung cancer in never smokers-the East Asian experience.

Authors:  Fei Zhou; Caicun Zhou
Journal:  Transl Lung Cancer Res       Date:  2018-08

Review 9.  Clinicopathological and demographical characteristics of non-small cell lung cancer patients with ALK rearrangements: a systematic review and meta-analysis.

Authors:  Liang Fan; Yun Feng; Huanying Wan; Guochao Shi; Wenquan Niu
Journal:  PLoS One       Date:  2014-06-24       Impact factor: 3.240

10.  miR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type.

Authors:  Jiayu Li; Xuefei Li; Shengxiang Ren; Xiaoxia Chen; Yishi Zhang; Fei Zhou; Mingchuan Zhao; Chao Zhao; Xiu Chen; Ningning Cheng; Yinmin Zhao; Caicun Zhou; Fred R Hirsch
Journal:  Oncotarget       Date:  2014-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.